ICMLF Inaugural Lecture - TKIs now but what next?
2009-09-11 - English

TET2 alterations in the multistep onset of myeloproliferative disorders
2009-09-11 - English

Point mutations in PDGFRA in myeloproliferative disease
2009-09-11 - English

Genetic alterations in high-risk, "BCR-ABL1-like" ALL
2009-09-11 - English

Understand the genetic bases of high risk, Ph-negative ALL

Whole genome sequencing of Ph-positive ALL
2009-09-11 - English

Mitochondrial origin of intracellular ROS in CML
2009-09-11 - English

Alternatives NHEJ is a novel therapeutic target in a subset of imatinib resistant CML patients
2009-09-11 - English

Results of SNP-arrays in various phases
2009-09-11 - English

Defining and targeting LSC
2009-09-11 - English

Effects of IFNa on LSC
2009-09-11 - English

FoxO involvement in CML
2009-09-12 - English

Glucocorticoid induced leucine zipper overcomes TKI resistance
2009-09-12 - English

Resistance profile of bosutinib using a high throughput sequencing assay
2009-09-12 - English

Future prospects
2009-09-12 - English

Front-line use of dasatinib and nilotinib
2009-09-13 - English

The second generation TKIs are currently used frontline within the frame of experimental trials. The endpoint of the presentation is to provide updated results obtained with nilotinib and dasatinib and how these results compare with those obtained with imatinib

Inhibiting autophagy in CML therapy
2009-09-13 - English

DEBATE: Do we need monitoring for FISH-negative patients? (FOR)
2009-09-13 - English

DEBATE: Do we need monitoring for FISH-negative patients? (AGAINST)
2009-09-13 - English